CD38 and Miyoshi myopathy: Radiolabeled conjugates of anti‐CD38 antibodies have been shown to detect MM in preclinical models and patients, with superior specificity and sensitivity compared to the routinely used [18F]FDG‐PET.[13, 19] However, the long biological half‐life of those antibody‐based imaging agents limits their applicability to patients who have received anti‐CD38 therapy.